ES2090325T3 - Inhibicion de rechazo de aloinjertos y xenoinjertos concordantes. - Google Patents

Inhibicion de rechazo de aloinjertos y xenoinjertos concordantes.

Info

Publication number
ES2090325T3
ES2090325T3 ES91907303T ES91907303T ES2090325T3 ES 2090325 T3 ES2090325 T3 ES 2090325T3 ES 91907303 T ES91907303 T ES 91907303T ES 91907303 T ES91907303 T ES 91907303T ES 2090325 T3 ES2090325 T3 ES 2090325T3
Authority
ES
Spain
Prior art keywords
rejection
xenointerges
conjunctional
allocation
inhibition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91907303T
Other languages
English (en)
Spanish (es)
Inventor
David James Graham White
Den Bogaerde Johan Beyers Van
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Imutran Ltd
Original Assignee
Imutran Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imutran Ltd filed Critical Imutran Ltd
Application granted granted Critical
Publication of ES2090325T3 publication Critical patent/ES2090325T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Compounds Of Unknown Constitution (AREA)
ES91907303T 1990-04-09 1991-04-04 Inhibicion de rechazo de aloinjertos y xenoinjertos concordantes. Expired - Lifetime ES2090325T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909007971A GB9007971D0 (en) 1990-04-09 1990-04-09 Pharmaceutical formulations

Publications (1)

Publication Number Publication Date
ES2090325T3 true ES2090325T3 (es) 1996-10-16

Family

ID=10674123

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91907303T Expired - Lifetime ES2090325T3 (es) 1990-04-09 1991-04-04 Inhibicion de rechazo de aloinjertos y xenoinjertos concordantes.

Country Status (22)

Country Link
EP (1) EP0527762B1 (enExample)
JP (1) JP3518547B2 (enExample)
CN (1) CN1040178C (enExample)
AT (1) ATE141167T1 (enExample)
AU (1) AU7555591A (enExample)
CZ (1) CZ283119B6 (enExample)
DE (1) DE69121401T2 (enExample)
DK (1) DK0527762T3 (enExample)
ES (1) ES2090325T3 (enExample)
GB (1) GB9007971D0 (enExample)
GR (1) GR3021642T3 (enExample)
HK (1) HK48597A (enExample)
IE (1) IE911153A1 (enExample)
IL (1) IL97788A (enExample)
IN (1) IN173149B (enExample)
MY (1) MY106158A (enExample)
NZ (1) NZ237739A (enExample)
PT (1) PT97277B (enExample)
SG (1) SG47465A1 (enExample)
SK (1) SK279949B6 (enExample)
WO (1) WO1991015221A1 (enExample)
ZA (1) ZA912467B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE297217T1 (de) 1999-10-27 2005-06-15 Alexandra Lucas Zusammensetzung zur vorbeugung und behandlung von transplantatabstossung
US7419670B2 (en) 2000-09-29 2008-09-02 Viron Therapeutics, Inc. Method of treating arthritis with SERP-1 and an immunosuppressant
EP2338511A3 (en) * 2004-05-14 2012-07-25 Alexion Pharmaceuticals, Inc. Prolongation of survival of an allograft by inhibiting complement activity
US7285530B2 (en) 2004-10-21 2007-10-23 Viron Therapeutics, Inc. Use of SERP-1 as an antiplatelet agent
LT3028716T (lt) 2006-10-10 2020-12-10 Regenesance B.V. Komplemento slopinimas nervų regeneracijos pagerinimui
JP6223659B2 (ja) 2008-11-10 2017-11-01 アレクシオン ファーマシューティカルズ, インコーポレイテッド 補体関連障害を処置するための方法および組成物
AU2014306002B2 (en) 2013-08-07 2017-05-25 Alexion Pharmaceuticals, Inc. Atypical hemolytic uremic syndrome (aHUS) biomarker proteins
WO2026064591A1 (en) * 2024-09-20 2026-03-26 Antinous Technology Company Limited Methods and compositions for preventing herpes virus reactivation in organ xenograft

Also Published As

Publication number Publication date
HK48597A (en) 1997-04-25
IL97788A (en) 1998-02-08
JPH05507266A (ja) 1993-10-21
IE911153A1 (en) 1991-10-09
DK0527762T3 (da) 1996-09-02
CN1056240A (zh) 1991-11-20
GR3021642T3 (en) 1997-02-28
SG47465A1 (en) 1998-04-17
IN173149B (enExample) 1994-02-19
GB9007971D0 (en) 1990-06-06
EP0527762A1 (en) 1993-02-24
PT97277B (pt) 1998-08-31
AU7555591A (en) 1991-10-30
MY106158A (en) 1995-03-31
ZA912467B (en) 1992-12-30
CN1040178C (zh) 1998-10-14
EP0527762B1 (en) 1996-08-14
IL97788A0 (en) 1992-06-21
WO1991015221A1 (en) 1991-10-17
ATE141167T1 (de) 1996-08-15
JP3518547B2 (ja) 2004-04-12
CZ283119B6 (cs) 1998-01-14
NZ237739A (en) 1993-09-27
DE69121401T2 (de) 1996-12-12
SK279949B6 (sk) 1999-06-11
CS9100988A2 (en) 1991-12-17
PT97277A (pt) 1992-01-31
DE69121401D1 (de) 1996-09-19

Similar Documents

Publication Publication Date Title
MX173183B (es) Uso de la rapamicina para la preparacion de una composicion para inhibir el rechazo de transplantes de organos o tejidos en un mamifero que lo necesita
ES2178036T3 (es) Derivados de ciclosporina, su preparacion y las composiciones farmaceuticas que le contienen.
BG100474A (bg) О-арил, о-алкил, о-алкенил и о-алкинил-макролидис имуносупресивно действие
ZA853690B (en) Immunoregulation
ATE185548T1 (de) Verwendung von n-arylmethylen ethylendiamintriacetate, n-arylmethylen iminodiacetat oder n,n'-diarylmethylen ethylendiamindiacetat gegen oxidativen stress
DE69733353D1 (de) Immunsuppressive wirkstoffe und verfahren
CO4700485A1 (es) Anticuerpos anti-icam-1 modificados y su uso en el tratamiento de inflamaciones
FR2707259B1 (fr) Poche à fermeture à glissière et procédé de fabrication de celle-ci.
NO953372L (no) Anvendelse av lamotrigin ved behandling av neuro-AIDS
DK0527762T3 (da) Inhibering af allotransplantat- og konkordant xenotransplantatafstødelse
ES2172536T3 (es) Liberacion y movilizacion de celulas hematopoyeticas.
NO20035434D0 (no) Behandling eller profylakse av transplantasjonsavst degree tning av insulinproduserende celler
ES2055415T3 (es) S-adenosil-metionina para el tratamiento de pancreatitis y del inmunorechazo del trasplante de pancreas.
AU8216691A (en) Autobiotics and their use in eliminating nonself cells in vivo
IT1273751B (it) Derivati azaciclici
ES2124327T3 (es) Derivados de sulfonamida aminometileno como inmunosupresores.
ATE165997T1 (de) Mehrstufiger scheibenfilter
AU3779693A (en) Antibodies for and treatment to prevent or reduce the severity of xenograft rejection
DE69109539D1 (de) Verminderung und Inhibition des Gehalts von Äthylenthioharnstoff in Alkylenbisdithiocarbamaten.
DE69124252D1 (de) Oberflächen-abriebbehandlung für kleine gegenstände
PL308551A1 (en) Application of bhpa compounds in combination with other nucleosidal inhibitors of reverse transcriptase in treating hiv infections
FR2712322B1 (fr) Cloison amovible et ses éléments constitutifs.
Bäckman et al. Late Graft Loss After Liver Transplantation: A Study of 432 Consecutive Patients
ITDP950007A1 (it) Detergenete polivalente
DK376587A (da) Methylenchloridbaseret middel til anvendelse ved affedtning af metaller

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 527762

Country of ref document: ES

FG2A Definitive protection

Ref document number: 527762

Country of ref document: ES